Thursday, October 8, 2015

Cytomx Sees Pop In IPO

South San Francisco-based Cytomx had its IPO debut this morning, pricing last night at $12.00 per share, and rising as high as $17.02 this morning immediately after its IPO. The developer of cancer therapeutics was venture backed by Third Rock Ventures, Canaan Partners, Roche Venture Fund, Casdin Capital, Cormorant Asset Management, Deerfield Management, Fidelity Management & Research Company, Perceptive Advisors, Pfizer Venture Investments, Redmile Group, Tekla Healthcare Investors, Tekla Life Sciences Investors, Venrock Healthcare Capital Partners and Wellington Management Company. The company had priced below its initial estimated pricing range of $14.00 to $16.00 per share, but was trading up around 20%, near $14.48, in mid-day trading on the Nasdaq as CTMX.